A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters

Ub, Lindberg; Crona, N.; Stigendal, Lennart; Teger‐Nilsson, Ann‐Catrine; Silfverstolpe, G.

doi:10.1016/0378-5122(89)90251-x

Cited by 35 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[27][28][29][30] Some authors observed AT-III reduction with ethinyl estradiol [31][32][33] and with estradiol valerate. 32,33 On the other hand, AT-III reduction during HT with oral CEE was not observed by others, but this may be due to methodology. For example, the Gilabert 34 conducted a transversal study where AT-III was measured only once, and Elzelsberger et al 35 measured AT-III levels by an immunological method.…”

Section: Discussionmentioning

confidence: 99%

Effect of Estrogen-Progestin Hormonal Replacement Therapy on Blood Coagulation and Fibrinolysis in Postmenopausal Women

Bonduki

Lourenço

Motta

et al. 2007

Clinics

View full text Add to dashboard Cite

Tests were performed before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of treatment. AT was determined by an amidolytic method, whereas F1+2 and TAT complex were measured by ELISA. RESULTS: There was a significant reduction in the AT level of patients who received oral CEE plus MP at T3. There was no AT reduction in patients taking either oral CEE alone or transdermal 17beta-estradiol plus MP. F1+2 increased in all patients, but it reached statistical significance only in patients receiving transdermal 17beta-estradiol MP at T3. CONCLUSIONS: The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-estradiol plus MP does not change AT. These changes might not be clinically relevant in the general population; however, hormonal replacement therapy may increase the risk of thrombosis in women with congenital or acquired thrombophilia.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Estrogen-Progestin Hormonal Replacement Therapy on Blood Coagulation and Fibrinolysis in Postmenopausal Women

Bonduki

Lourenço

Motta

et al. 2007

Clinics

View full text Add to dashboard Cite

show abstract

“…Дан-ные зарубежных исследований говорят о том, что эффект E 2 B в отношении индукции синтеза белков печени, таких как синтез ангиотензиногена, транс-портных белков, факторов коагуляции, менее выра-жен в сравнении с ЕЕ [2,4,5,7].…”

Section: Discussionunclassified

The influence of oral combined oral contraceptive with estradiol valerate and dienogest on hemostatic system

Андреева¹,

Grigoryan²

2015

Probl. reprod.

View full text Add to dashboard Cite

Objective. To compare the hemostatic effects of the four-phasic E2B/dienogest (DNG) COC with a monophasic low-estrogen dose COC containing ethinylestradiol/levonorgestrel (LNG). Мaterial and methods. 30 women were divided into two equal groups to receive E2B/DNG or EE/LNG. Hemostatic parameters were evaluated at baseline and after three cycles of therapy. Results. D-dimer level changes were significantly less pronounced with E2B/DNG compared with EE/LNG (p<0,05). Other hemostatic parameters had no any significant changes in both groups. Conclusion. The COC with E2B/DNG had less pronounced effects on hemostatic parameters than EE/LNG.

show abstract

“…Estradiol valerate is considerably less potent than ethinylestradiol in terms of hepatic protein synthesis induction, as demonstrated in clinical studies assessing SHBG, angiotensinogen, and hemostatic parameters. [26][27][28][29] However, changes observed with COCs reflect not only influences of the estrogen component, but also those of the progestogen component; indeed, progestogen can affect the binding of testosterone or cortisol to transport proteins [33] and the clearance time from serum. [34] The findings of the current study are also consistent with those of a study that compared the Table III.…”

Section: Discussionmentioning

confidence: 99%

“…[24] Moreover, 17b-estradiol levels have been shown to be stable throughout the cycle, with estrogen levels remaining comparable with those during the early follicular phase. [25] Based on studies that have evaluated the effect of 17b-estradiol versus ethinylestradiol on hepatic protein synthesis, [26][27][28][29] it is expected that estradiol valerate/dienogest will have a considerably reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance.…”

Section: Introductionmentioning

confidence: 99%

Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive

Klipping¹,

Duijkers²,

Parke

et al. 2011

Drugs R D

View full text Add to dashboard Cite

Background: A novel estradiol-based combined oral contraceptive (COC) is currently available in many countries worldwide, including Europe and the US. Based on previous studies, it is expected that this estradiol-based COC will have a reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance. Objective: The aim of this study was to compare the hemostatic effects of the estradiol valerate/dienogest COC with a monophasic low-estrogen dose COC containing ethinylestradiol/levonorgestrel. Study Design: Healthy women aged 18-50 years were randomized to receive a COC containing estradiol valerate/dienogest (2 days estradiol valerate 3 mg, 5 days estradiol valerate 2 mg/dienogest 2 mg, 17 days estradiol valerate 2 mg/dienogest 3 mg, 2 days estradiol valerate 1 mg, 2 days placebo) or ethinylestradiol 0.03 mg/levonorgestrel 0.15 mg in a crossover study design. Women received each treatment for three cycles, with two washout cycles between treatments. The primary efficacy variables were the intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle three. Results: Data from 29 women were assessed. Intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle three were less pronounced with estradiol valerate/dienogest than with ethinylestradiol/ levonorgestrel. Conclusion: The novel COC containing estradiol valerate/dienogest had similar or less pronounced effects on hemostatic parameters than ethinylestradiol/levonorgestrel.

show abstract

A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters

Cited by 35 publications

References 0 publications

Effect of Estrogen-Progestin Hormonal Replacement Therapy on Blood Coagulation and Fibrinolysis in Postmenopausal Women

Effect of Estrogen-Progestin Hormonal Replacement Therapy on Blood Coagulation and Fibrinolysis in Postmenopausal Women

The influence of oral combined oral contraceptive with estradiol valerate and dienogest on hemostatic system

Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive

Contact Info

Product

Resources

About